The Anti-Diabetes Drugs market in Fiji has been evolving over the years due to various factors.
Customer preferences: Fijians tend to prefer traditional medicine over modern medicine. However, with the rise in diabetes cases, there has been an increase in the demand for Anti-Diabetes Drugs. Patients are now willing to try modern medicine to manage their condition, but they still prefer natural remedies.
Trends in the market: The Anti-Diabetes Drugs market in Fiji has been growing steadily due to the increase in diabetes cases. There has been a rise in the number of people diagnosed with diabetes, which has led to an increase in demand for Anti-Diabetes Drugs. The market has also seen a shift towards more affordable generic drugs.
Local special circumstances: Fiji has a high prevalence of diabetes, with more than 30% of the population affected by the disease. This has led to an increase in demand for Anti-Diabetes Drugs. However, the country faces challenges such as limited access to healthcare facilities, which makes it difficult for patients to access medication. Additionally, the country has a large rural population, which makes it harder for them to access medication.
Underlying macroeconomic factors: The Fijian government has been working to improve the healthcare system in the country. The government has been investing in healthcare infrastructure and has also introduced policies to make healthcare more affordable for the population. This has led to an increase in demand for Anti-Diabetes Drugs. Additionally, the country has been experiencing economic growth, which has led to an increase in disposable income. This has made it easier for patients to afford medication.In conclusion, the Anti-Diabetes Drugs market in Fiji has been growing due to the rise in diabetes cases. Patients are now willing to try modern medicine to manage their condition, but they still prefer natural remedies. The market has also seen a shift towards more affordable generic drugs. The Fijian government has been investing in healthcare infrastructure, which has led to an increase in demand for Anti-Diabetes Drugs. However, the country faces challenges such as limited access to healthcare facilities, which makes it difficult for patients to access medication.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
